Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-10-16
1998-11-24
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142358, 514255, 514341, 514367, 514375, 544111, 544138, 544139, 544370, 546 44, 546210, 548152, 548217, 548159, 5483127, 5482415, 5483147, 5483154, 5483355, 5483401, 5483415, 5483435, A61K 31415, C07D23356, C07D23304, C07D23302, C07D23361
Patent
active
058407219
ABSTRACT:
The present invention relates to polysubsituted imidazole having formula 1 ##STR1## These compounds are useful for restoring the sensitivity of multidrug resistant cells to cancer chemotherapeutic agents.
REFERENCES:
patent: 2801243 (1957-07-01), Hanslick et al.
patent: 3361755 (1968-01-01), Green
patent: 3558645 (1971-01-01), Griot
patent: 3707475 (1972-12-01), Lombardino
patent: 3784557 (1974-01-01), Cescon
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4424229 (1984-01-01), Jorgensen et al.
patent: 4632930 (1986-12-01), Carini et al.
patent: 4665023 (1987-05-01), Deneke et al.
patent: 4914096 (1990-04-01), Houlihan et al.
patent: 5274095 (1993-12-01), Braun et al.
patent: 5292699 (1994-03-01), Guder et al.
patent: 5296609 (1994-03-01), McCort et al.
patent: 5312828 (1994-05-01), Finkelstein et al.
patent: 5700826 (1997-12-01), Mjalli et al.
Engel et al, Liebigs Am. Chem., vol. of 1978, pp. 1916 to 1927.
Matsuda et al, Chemistry Letters, vol. of 1977, pp. 1456 to 1460.
Novelli et al, Terahedron Letters, No. 3, pp. 256 to 269 (1967).
Palkowitz et al, J. Med. Chem., vol. 37, pp. 4508 to 4521 (1994).
Salimbeni et al, J. Med. Chem., vol. 37, pp. 3928 To 3938 (1994).
Bradley et al., P-Glycoprotein Expression in Multidrug-resistant Human Ovarian Carinoma Cell Lines, Cancer Research, May 15, 1989, 2790-2796, 49.
Raderer and Scheithaurer, Clinical Trials of Agents that Reverse Multidrug Resistance, Cancer, Dec. 15, 1993, 3553-3563, 72-12.
Juranka et al., P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins, The FASEB Journal, Dec. 1989, 2583-2592, 3.
Krishnamachary and Center, The MRP Gene Associated with a Non-P-glycoprotein Multidrug Resistance Encodes a 190-kDa Membrane Bound Glycoprotein, Cancer Research, Aug. 15, 1993, 3658-3661, 53.
Leyland-Jones et al., Reversal of Multidrug Resistance to Cancer Chemotherapy, Cancer Supplement, Dec. 1, 1993, 3484-3488, 72-11.
Lum et al., Clinical Trials of Modulation of Multidrug Resistance, Cancer Supplement, Dec. 1, 1993, 3502-3514, 72-11.
Krieg and Manecke, Synthese und Halbleitereigenschaften arylsubstituierter Imidazole, A. Naturforschg teil, Sep. 1966, 132-141, 22b.
Bader et al., Nucleophilic Displacements of Activated Fluorine in Aromatic Compounds, J. Organic Chemistry, Jul. 1966, 2319-2321, 31.
Garro-Helion, et al., Mild and Selective Palladium(O)-Catalyzed Deallylation of Allylic Amines, J. Organic Chemistry, 1993, 6109-6113, 58-22.
Patel et al., Palladium-Catalyzed Vinylic Substitution Reactions with Carboxylic Acid Derivatives, J. Organic Chemistry, 1977, 3903-3907, 42-24.
Mjalli Adnan M. M.
Zhang Chengzhi
Chow Frank S.
Higel Floyd D.
Ontogen Corporation
LandOfFree
Imidazole derivatives as MDR modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole derivatives as MDR modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole derivatives as MDR modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1702437